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Background: Roux-en-Y gastric bypass (RYGB) is the gold standard method for bariatric surgery and leads to 
substantial improvements in Type 2 Diabetes mellitus. However, many patients experience relapses in 
diabetes five years after undergoing this aggressive surgical procedure. We focus on beta-cell population 
changes and absorptive intestinal consequences after RYGB in a healthy nonobese animal model after a long 
survival period. 
Methods: For our purpose, we use three groups of Wistar rats: RYGB-operated, surgical control (Sham) and 
fasting control. We measure alpha-, beta-cell mass; transcription (Arx, and Pdx-1) and proliferation (Ki67) 
factors; glucose tolerance and insulin release after oral glucose tests; histological adaptive changes in the 
jejunum; and intestinal glucose transporters. 
Results: Our results showed an early increase in insulin secretion after surgery, that decrease at the end of 
the study. The beta-cell mass reduces twenty-four weeks after RYGB, which coincides with decrease of Pdx- 
1 transcription promoter factor. These was coincident with an increase in alpha-mass and a high expression 
of Arx in RYGB group. 
Conclusions: The analysis of all data showed beta-cell mass transdifferentiation into alpha-cell mass in 
RYGB rats. Due to long-term exhaustion of the beta-cell population by hyperinsulinism derived from di-
gestive tract adaptation to surgery. 
© 2021 The Author(s). Published by Elsevier GmbH. 
CC_BY_NC_ND_4.0   
1. Introduction 
Roux-en-Y gastric bypass (RYGB) has been determined to be a 
powerful therapy for improving obesity and Type 2 Diabetes mellitus 
(T2DM), even prior to weight loss (Pournaras et al., 2016). To explain 
this finding, many studies have reported increased GLP-1 plasma 
levels due to its enhanced release by L-cells in the ileum after sur-
gery (Shah et al., 2014). This hormone has remarkable effects on 
beta-cell insulin secretion (Yabe and Seino, 2011) and beta-cell 
proliferation (Prada et al., 2019). However, the key role of GLP-1 in 
T2DM remission after glucose level restoration in GLP-1-deficient, 
diabetic, RYGB-operated mice is controversial (Mokadem et al., 
2013). The peptide tyrosine-tyrosine (PYY), which is also secreted by 
L cells, has been proposed to be a key factor in glucose improvement 
after RYGB. PYY induces increased insulin and glucagon secretion 
from islets (Ramracheya et al., 2016). 
RYGB also causes adaptive changes in the alimentary limb. These 
changes include long-term absorbent surface hypertrophy and 
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increased glucose and protein absorption patterns (Seeley et al., 
2015). These changes enhance the expression of glucose transpor-
ters, such as SGLT1, GLUT2, GLUT3, GLUT4 or GLUT5, in response to 
the loss of absorption area after surgery (Cavin et al., 2016). 
These seem to suggest the physio-pathological basis for diabetes 
remission after RYGB. However, many RYGB patients experience 
reversal of T2DM improvement. Approximately 21.2–38.9% of pa-
tients present with T2DM relapse three years after surgery; the 
percentage of diabetes relapse reaches 33.1–50.8% five years after 
surgery (McTigue et al., 2020; Wang et al., 2020). 
Many studies have reported a great plasticity of the beta–cell 
mass to dedifferentiate into alpha-cells under stressful conditions 
with high insulin requirements (Swisa et al., 2017). In these situa-
tions, beta-cells lose their markers, such as transcription insulin 
promoter factor (Pdx-1), or insulin production (Gao et al., 2014; 
Talchai et al., 2012). Instead, these cells express alpha-cell lineage 
markers, such as Aristaless-related homeobox protein (Arx). 
We hypothesized that these factors could be involved in the in-
stances of T2DM relapse after RYGB surgery. Beta-cell population 
plasticity with increased glucose uptake, as an adaptive response of 
the alimentary limb after RYGB, leads to a long-term condition of 
hyperinsulinemia. The reduced alimentary limb after surgery 
shortens the absorption surface, and consequently, the jejunum 
surface undergoes an adaptation process with elongated villi (Cavin 
et al., 2016). The consequence of these absorption peaks is a high 
demand for insulin release, which can lead to beta-cell exhaustion in 
the long-term (Abdel-Hamida and Firganya, 2019). Finally, RYGB 
could lead to a relapse of previously improved T2DM. 
To this end, we used a nonobese healthy model of Wistar rats 
that underwent RYGB surgery. We analyzed the long-term beta-cell 
population response in order to explain T2DM relapse after RYGB. 
After surgery, we investigated histological and functional para-
meters after alimentary limb adaptation by measuring glucose 
transporter expression. 
2. Material and methods 
2.1. Animals and protocols 
Thirty-six male Wistar rats weighing approximately 200–220 g 
and aged 10–11 weeks were provided by and housed at the 
Experimentation and Animal Production Service of University of 
Cádiz (SEPA). The animal procedures were performed with the ap-
proval of the University of Cádiz Committee for the Ethical Use and 
Care of Experimental Animals, and every experiment was performed 
in accordance with the relevant international guidelines and reg-
ulations related to animal welfare. 
All the Wistar rats were randomly divided into three groups 
(n = 12 each): Fasting control (FG), Sham and Roux-en-Y gastric 
bypass (RYGB). Half of the animals (n = 6) in each of the three groups 
were sacrificed twelve weeks after surgery, and the remaining ani-
mals (n = 6) were sacrificed twenty-four weeks after surgery. The 
animals in the FG group (n = 12) underwent the same perioperative 
fasting periods described in the surgical protocol. All the animals 
finished a 12-h presurgical and 12-h postsurgical fasting period. An 
intake readaptation period followed the surgeries to normalize 
fasting. Weight was measured every three days beginning from the 
day of surgery until the fourth week of survival. 
2.2. Surgical procedures: weight measurement 
The surgical procedures were performed on anesthetized animals 
using a continuous infusion of isoflurane 2–4% V/V (Abbott 
Columbus, OH, USA). The sham technique (Sham) (n = 12) re-
produced surgical damage near the intestine, but its integrity was 
maintained. Sham was performed with a laparotomy of 5 cm in the 
upper third of the abdomen and an incision of approximately 3 cm in 
the middle area of the abdomen. The jejunum was transected 40 cm 
distal to the angle of Treitz, with terminus-terminus anastomosis. 
The abdominal muscular and skin layers were closed in one layer 
using a continuous suturing technique. 
In the RYGB group of rats (n = 12) were subjected to a pre- and 
postsurgical 12-hour fasting period. Animals were anesthetized with 
continuous infusion of 3% V/V isoflurane (Isoflo, Abbott 571329.8, 
Madrid, Spain). A laparotomy of 3 cm was made in the midline of the 
abdomen, and a gastric pouch with a volume of approximately 30% 
of the normal gastric volume was created (Fig. 1). The remnant 
gastric fundus was anastomosed to the jejunum at 14 cm distal from 
the ligament of Treitz. The abdominal muscular and skin layers were 
closed in one layer using a continuous suturing technique. 
The weight gain of each animal in the three groups was mea-
sured every 48 h for forty days after surgery. The weight gain is 
expressed as medium daily weight gain in grams. 
Fig. 1. 1.A. RYGB schema. 1B. Surgical technique in RYGB. A laparotomy of 3 cm was performed in the midline of the abdomen (1), sectioning the gastrosplenic ligament (2) and 
exposing the stomach. A gastric pouch with a volume of approximately 30% of the normal gastric volume was created (3), and this pouch included the corpus and antrum (4). The 
remnant gastric fundus was anastomosed to the jejunum 14 cm distal from the ligament of Treitz (5). 
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2.3. Oral glucose tolerance test (OGTT) 
Three, eleven and twenty-three weeks after surgery, an oral 
glucose tolerance test (OGTT) was performed with the FC, Sham and 
RYGB groups. To this end, the animals were subjected to a 12-hour 
fasting period. A 20% v/v D-glucose solution (2 g/kg) was adminis-
tered by gavage. Glycemia was measured by a Glucocard G-Meter 
1810 glucometer (Menarini Diagnostics, Italy) in blood samples ob-
tained from rat tails at 0, 30, 60, 90 and 120 min after glucose so-
lution administration. 
In each group, three, eleven and twenty-three weeks after sur-
gery, insulin measurement was performed in blood samples ob-
tained from the tails every 10 min for 60 min. For this oral glucose 
insulin test (OGIT), the rats were subjected to a 12-hour fasting 
period, and then, a glucose solution was administered. We used an 
ELIZA kit (ALPCO Diagnostics, Salem, NH, USA). 
The area under the curve (AUC) was calculated according to the 
trapezoidal rule for both parameters. 
2.4. D-Xylose absorption test 
Eleven and twenty-three weeks after surgery, D-xylose absorp-
tion assay was performed in FC, Sham and RYGB. A D-xylose solution 
(0.8 g/kg body weigh) was administered through gavage, and plasma 
D-xylose levels were measured at 0, 60, 120 and 180 after load using 
spectrophotometric method as described Roe and Rice. Values ob-
tained were expressed as D-xylose mmol/plasma ml. 
Areas under curve (AUCs) were calculated by trapezoidal rule for 
each parameter in the study and expressed as plasma glucose mg/dl 
min-1, plasma insulin μU/ml min-1 and D-xylose mmol/ml min − 1. 
2.5. Sacrifice and tissue preparation 
Six animals from each group were sacrificed twelve weeks after 
surgery by isoflurane overdose via inhalation. The remaining 6 ani-
mals in the group were sacrificed twelve weeks later by isoflurane 
overdose via inhalation. Pancreas and gut samples were immediately 
removed and fixed in Bouin’s solution overnight at 4 °C. Later, the 
samples were dehydrated, embedded in paraffin and cut into 8 µm 
microtome sections. 
2.6. Pancreas immunostaining 
Rehydrated sections of the pancreas, beta and alpha-cell masses 
were analyzed by immunostaining using guinea pig anti-insulin IgG 
antibodies (1/1000, Sigma Aldrich, St Louis MO, USA) and rabbit anti- 
glucagon IgG antibodies (1/5000, Abcam, Cambridge, CB4 OFL, UK). 
The fluorescent conjugated secondary antibodies (Alexa 546 and 
488, 1/400 and 1/200 titers, respectively; Molecular Probes Inc. 
Eugene, OR, USA) were used. DAPI was used to counterstain the 
nuclei. Beta- and alpha-cell masses were calculated by multiplying 
the positive islet area/total pancreatic area ratio, by the total pan-
creatic weight (respectively, insulin- or glucagon- positive islet area). 
The results were expressed as milligrams (mg). These operation was 
performed three times in each animal and the results was expressed 
as the mean ±  SEM. 
The alpha-cell proliferation ratio was calculated by double im-
munostaining using rabbit anti-Ki67 IgG antibodies (1/50 titer, 
Abcam, Cambridge, CB4 OFL, UK) and mouse anti-glucagon IgG an-
tibodies. The transcription factors Arx and Pdx-1 were also analyzed 
using rabbit anti-Arx IgG and rabbit anti-Pdx-1 antibodies (1/200 
and 1/500, respectively; Abcam, Cambridge, CB4 OFL, UK). The 
fluorescent secondary antibodies were conjugated to Alexa 546 and 
488 (1/400 and 1/200 titers, respectively, Molecular Probes Inc. 
Eugene, OR, USA). DAPI was used to counterstain the nuclei. Beta- 
and alpha-cell masses were calculated by multiplying insulin- or 
glucagon-positive area/total pancreatic area ratio/pancreatic weight, 
and the results are expressed as milligrams (mg). 
The alpha-cell proliferation ratio was quantified in 50 islets per 
condition. The results were observed under randomized conditions 
by a single investigator and expressed as the number of glucagon- 
positive cells/Ki67-positive cells/mm2 of the glucagon-positive area. 
The numbers of Arx- and Pdx-1-positive cells per condition were 
evaluated in five nonserial slices of whole pancreas and expressed as 
the number of Arx- or PDX-1-positive cells/mm2 of pancreas. 
Using pancreas slices from the three animal groups, beta–cell 
apoptosis was determined using the Dead-End-Fluorometric term-
inal deoxynucleotidyltransferase-mediated 2´-deoxyuridine 5´-tri-
phosphate nick end labeling system (TUNEL) (Promega, Madison, 
WI, USA) according to the manufacturer’s instructions. Insulin was 
simultaneously stained using polyclonal guinea pig anti-insulin an-
tibodies (Sigma-Aldrich, St Louis MO, USA). The fluorescent sec-
ondary antibodies were conjugated to Alexa 546 (1/400 titer, 
Molecular Probes Inc., Eugene, OR, USA). The apoptosis ratio was 
quantified in 30 islets per condition. The results were noted under 
randomized conditions by a single investigator and expressed as the 
number of TUNEL-positive and insulin-positive cells/mm2 of islets. 
2.7. Gut immunostaining and histological study 
Ten nonserial rehydrated sections from the gut samples of each 
rat were analyzed by immunostaining using rabbit anti-SGLT1 IgG 
(1/500 titer, Abcam, Cambridge, CB4 OFL, UK), rabbit anti-GLUT1 IgG 
(1/200 titer, Bioss Inc., Woburn MA, USA) and rabbit anti-GLUT5 IgG 
(1/200 titer, Thermo-Fisher Inc., Burnaby, BC V5C 6S5, Canada). 
Samples from the intestinal tubes of the RYGB-operated rats were 
selected from the alimentary limbs, while samples from the 
equivalent part of the jejunum were collected from the Sham-op-
erated rats group. The fluorescent secondary antibodies were con-
jugated to Alexa 546 and 488 (1/400 and 1/200 titers, respectively; 
Molecular Probes Inc. Eugene, OR, USA). DAPI was used to counter-
stain the nuclei. The values are expressed as SGLT-1-, GLUT1- or 
GLUT5-positive area/total intestinal area. 
In addition, villus height and crypt depth were measured with 
eosin-hematoxylin-stained slices. Samples were selected from the 
alimentary limbs of the RYGB-operated animals or from equivalent 
parts of the jejunum of the Sham-operated animals. The values were 
expressed as length in μm. The histological parameters were mea-
sured and noted by a single investigator using a fluorescence mi-
croscope with a digital camera and Cell-D image analysis software 
(Olympus, GmbH. Hamburg, Germany). 
2.8. Statistical analysis 
The data are presented as the means ±  SEM. For OGTT and in-
sulin, AUC, histological and weight gain data analysis, one-way 
ANOVA followed by Tukey's/Bonferroni´s post hoc test was con-
ducted using SPSS v21.0 software. Statistical significance was ac-
cepted at P  <  0.05. 
3. Results 
3.1. Weight gain 
We measured the weight gain in the FC, Sham and RYGB groups 
forty days after surgery (Fig. 2). There were no differences between 
any of the groups from the first day to the thirty-fourth day, but 
significant differences were observed between the control groups 
and the RYGB group beginning on the thirtieth day (P  <  0.05) or 
from the thirty-second day to the end of the study (P  <  0.01). 
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3.2. OGTT and OGIT 
Three, eleven and twenty-three weeks after surgery, OGTT was 
performed on the animals in the FC, Sham and RYGB groups. Similar 
curves were observed in the three groups, with no significant dif-
ferences between the glucose tolerance patterns of all the groups in 
the OGTT tests three and eleven weeks after surgery (Fig. 3A and 3B). 
However, a significantly high plasma glucose level in the RYGB group 
was observed (Fig. 3C). In the OGTT performed at twenty-three 
weeks after surgery, high glucose was observed thirty and sixty 
minutes after glucose administration (Fig. 3E). The area under the 
curve (AUC) was calculated for the three groups at three, eleven and 
twenty-three weeks after surgery. No significant differences be-
tween the FC, Sham and RYGB AUCs were found at the third or 
eleventh week (Figs. 3B and 3F). An increased AUC was observed in 
the RYGB-operated rats compared with the FC rats but not compared 
with the Sham rats at twenty–third weeks of survival (Fig. 3J). 
Insulin secretion was analyzed after OGIT at the third, eleventh 
and twenty-third weeks of the study. A high plasma insulin secretion 
pattern was observed in the RYGB animals compared with both 
controls in the first and second OGIT tests (Fig. 3C and 3G). However, 
the RYGB insulin secretion pattern showed a significant decrease in 
the RYGB group compared to the control group in the last third test. 
The third OGIT was performed at the twenty-third week of survival 
(Fig. 3K). The insulin secretion AUCs after every OGIT were also 
measured. Increased AUC values were observed for the RYGB group 
compared with the control group after the first and second OGITs 
(Figs. 3D and 3H). However, the RYGB plasma insulin AUC was sig-
nificantly decreased compared with the control plasma insulin AUC 
at twenty-three weeks after surgery, as shown in Fig. 3L. 
3.3. D-Xylose absorption assay 
Eleven and twenty-three weeks after surgery D–xylose absorp-
tion assay were performed on FC, Sham and RYGB groups. An in-
creased absorption pattern appeared on RYGB curve respect to FC 
and Sham (Fig. 4A and 4C). Also significant increasing was observed 
between plasma D-xylose AUC from RYGB rats and controls at eleven 
and twenty-three weeks after surgery (Figs. 4B and 4D). 
3.4. Pancreas immunostaining 
The beta- and alpha-cell masses in the whole pancreas slices 
from the RYGB, FC or Sham rats were analyzed twelve and twenty- 
four weeks after surgery. The beta-cell mass exhibited a significant 
decrease between twelve and twenty-four weeks after surgery, 
as shown in Fig. 5A. Statistical differences appeared between the 
Fig. 2. Weight was measured every 48 h on each animal from n = 12 FC, n = 12 Sham 
and n = 12 RYGB groups, along forty days after surgery. It was expressed as medium 
daily weight gain in grams. 
Fig. 3. 3A, 3E and 3L. Glucose levels, after the three OGTT, in fasting control (FC) (continuous blue line with circles), sham-operated (Sham) (discontinuous black line with 
squares), and RYGB rats (discontinuous red line with triangles). Glucose levels are represented as mg/dl in the Y axis versus time after glucose ingestion in the X axis. Values are 
expressed as the mean ±  SEM. 3B, 3F and 3J. Glucose plasma area under curve (AUC) in fasting control (FC) (blue bar), sham-operated (Sham) (black lined bar), and RYGB rats (red 
bar), after the three OGTT. The values are presented as mg/dl min-1 in the Y axis, after the three OGTT, expressed as the mean ±  SEM. 3C, 3G and 3K. Plasma insulin in fasting 
control (FC) (continuous blue line with circles), sham-operated (Sham) (discontinuous black line with squares), and RYGB rats (discontinuous red line with triangles), after the 
three OGTT. Plasma insulin levels are represented as μU/ml in the Y axis versus time after glucose ingestion in minutes in the X axis. Values were expressed as the mean ±  SEM. 3D, 
3H and 3L. Plasma insulin area under curve (AUC) in fasting control (FC) (blue bar), sham-operated (Sham) (black lined bar), and RYGB rats (red bar), after the three OGTT. The 
values were presented as μU/ml min-1 in the Y axis and expressed as the mean ±  SEM. 
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beta-cell mass of the RYGB animals twenty-four weeks after surgery 
and that of the control animals (Fig. 5A). On the other hand, at the 
twenty-fourth week of the study, we observed an increased alpha- 
cell mass in RYGB rats but not in any other group of rats (Fig. 5B). 
We analyzed beta- and alpha-cell proliferation ratios in the FC, 
Sham and RYGB groups, twelve and twenty-four weeks after surgery. 
As a proliferation marker, we used the presence of Ki67 positive 
staining on beta- or alpha-cell populations (Fig. 6C and 6D). The results 
show a significant increase in the beta-cell proliferation ratio in the 
RYGB rat group twelve weeks after surgery compared with that in the 
RYGB groups twenty-four weeks after surgery (P  <  0.01) and compared 
with that in the other groups in this study at every time (P  <  0.05) No 
significant difference in the alpha-cell proliferation ratio was observed 
between the RYGB, Sham and FC groups at any time studied. 
Fig. 4. 4.A. Plasma D-Xylose absorption assay insulin in fasting control (FC) (continuous blue line with circles), sham-operated (Sham) (discontinuous black line with squares), and 
RYGB rats (discontinuous red line with triangles), after eleven weeks after surgeries. Plasma D-xylose levels are represented as mmol/ml in the Y axis versus time after ingestion in 
minutes in the X axis. Values were expressed as the mean ±  SEM. 4.B. Plasma D-xylose area under curve (AUC) in fasting control (FC) (blue bar), sham-operated (Sham) (black lined 
bar), and RYGB rats (red bar), after eleven weeks after surgeries. The values were presented as mmol/ml min-1 in the Y axis and expressed as the mean ±  SEM. 4.C. Plasma D-Xylose 
absorption assay insulin in fasting control (FC) (continuous blue line with circles), sham-operated (Sham) (discontinuous black line with squares), and RYGB rats (discontinuous 
red line with triangles), after twenty-three weeks after surgeries. Plasma D-xylose levels are represented as mmol/ml in the Y axis versus time after ingestion in minutes in the X 
axis. Values were expressed as the mean ±  SEM. 4.D. Plasma D-xylose area under curve (AUC) in fasting control (FC) (blue bar), sham-operated (Sham) (black lined bar), and RYGB 
rats (red bar), after twenty-three weeks after surgeries. The values were presented as mmol/ml min-1 in the Y axis and expressed as the mean ±  SEM. 
Fig. 5. Beta-cells in red, alpha cells in green (Alexa 546 and 488 respectively), and DAPI (blue) counterstained nuclei in FC (5.1 and 5.4, at 12 and 24 weeks after surgeries), Sham 
(5.2 and 5.5, at 12 and 24 weeks after surgeries) and RYGB (5.3 and 5.6, at 12 and 24 weeks after surgeries) in pancreas samples. 5A. Beta-cell mass expressed in milligrams (mg) in 
the Y axis, as the mean ±  SEM in Fasting control (FC) (white bar), sham-operated (Sham) (lined bar), and RYGB rats (blue bar). The data show the two studied periods in the X axis. 
5B. Alpha-cell mass expressed in milligrams (mg) in the Y axis, as the mean ±  SEM in Fasting control (FC) (white bar), sham-operated (Sham) (lined bar), and RYGB rats (red bar). 
The data show the two studied periods in the X axis. 
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The Pdx-1 transcription factor, a differentiation marker in the 
beta-cell population, was measured by immunostaining. Loss of Pdx- 
1 expression was only detected in the RYGB-operated rat islets 
twenty–four weeks after surgery (Fig. 6A). These decreases were not 
observed at the twelfth week after surgery in either the FC or Sham 
groups at any time point. No other group at any time of the study or 
in RYGB at the initial period of study showed immunostaining in 
pancreatic islets. 
Finally, the expression of Arx, an alpha-cell differentiation 
marker, was examined in the pancreas samples. Markedly increased 
cellular expression was observed in the RYGB group twenty-four 
weeks after surgery. However, no other group in this study exhibited 
Arx expression at any time (Fig. 6B). 
The apoptosis beta-cell population ratio was measured twenty- 
four weeks after surgery in each group of the study using a Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. 
No significant difference was observed between the rats in the FC, 
Sham and RYGB groups (Fig. 6E). 
3.5. Intestinal immunostaining 
Several parameters, such as villus height, crypt depth or GLUT1, 
GLUT5 and SGLT1 expression, were measured in the intestinal tissue 
sections. Intestinal sections were selected from the alimentary limbs 
of the RYGB-operated rats. In the FC and Sham groups, the equivalent 
intestinal portion was the third proximal jejunum. These samples 
were obtained from the rats sacrificed both twelve and twenty-four 
weeks after surgery. 
An increased villus height was observed in the alimentary limb 
samples from the RYGB rats at the two points in the study. These 
data were not observed in the FC or Sham groups at any time of the 
study (Fig. 7A). Crypt depth was also analyzed, and a strong devel-
opment of crypts from the RYGB alimentary limb samples was 
observed but only at the final time point of the study, namely, 
twenty-four weeks after surgery. The FC and Sham groups did not 
show increased crypt depth development at any time (Fig. 7B). 
Glucose transporter expression on the intestinal surface of the 
alimentary limbs from the RYGB rats or on the equivalent intestinal 
sections from the FC and Sham rats was also tested. The presence 
and degree of expression of SGLT1 was measured three and twenty- 
four months after surgery. High expression of SGLT1 was detected in 
the alimentary limb surface of the RYGB rats at twelve and twenty- 
four weeks compared with the FC or Sham rats at those time points. 
(Fig. 8A). 
We also tested GLUT5 expression in each group. Markedly in-
creased GLUT5 expression was observed twenty-four weeks, but not 
twelve weeks, after surgery in the alimentary limbs of the RYGB rats 
(Fig. 8B). No GLUT1 expression differences were observed between 
the equivalent intestinal segments in the FC and Sham groups at any 
time point (Fig. 8C). 
4. Discussion 
The present data show an interesting long-term effect of RYGB on 
glucose homeostasis in our model. In particular, the present data 
show an early increase in insulin secretion after surgery in the RYGB 
group compared with the control group at approximately twelve 
weeks after surgery, and this secretion decreased as the study pro-
gressed, reaching levels lower than those observed in the controls at 
the twenty-third week of the study (Fig. 3). This finding led us to 
consider an insulin secretory failure and a possible beta cell-popu-
lation damage. That is why we investigated the beta-cell apoptosis 
ratio. However, no significant differences were observed among the 
groups (Fig. 6E). This finding is consistent with reports of the ne-
cessity of high plasma glucose levels to induce beta-cell apoptosis 
(Hui et al., 2004; Kim et al., 2005); because our model shows an 
early elevation of insulin secretion after RYGB and normal glycemia 
throughout most of the study. Surprisingly, the beta-cell mass was 
depleted twenty-four weeks after RYGB, as shown in Fig. 5A. The 
possibilities of beta-cell apoptosis and hepatic insulin resistance 
were excluded because Wistar rats are a healthy model. Few 
Fig. 6. 6A. Pdx-1 expression in beta-cell area as Pdx-1 + cells/mm2 of insulin + area in the Y axis, as the mean ±  SEM. Fasting control (FC) (blue bar), sham-operated (Sham) (lined 
bar) and RYGB rats (red bar). The data show the two studied periods in the X axis. 6B. Arx expression in beta-cell area as Arx+ cells/mm2 of insulin+ area in the Y axis, as the 
mean ±  SEM. Fasting control (FC) (blue bar), sham-operated (Sham) (lined bar) and RYGB rats (red bar). The data show the two studied periods in the X axis. 6C. Ki67 expression in 
beta-cell area as Ki67 + Insulin + cells/mm2 of area in the Y axis, as the mean ±  SEM. Fasting control (FC) (blue bar), sham-operated (Sham) (lined bar) and RYGB rats (red bar). The 
data show the two studied periods in the X axis. 6D. Ki67 expression in alpha-cell area as Ki67 + glucagon + cells/mm2 of area in the Y axis, as the mean ±  SEM. Fasting control (FC) 
(blue bar), sham-operated (Sham) (lined bar) and RYGB rats (red bar). The data show the two studied periods in the X axis. 6E. Apoptosis in beta-cell area as 
TUNNEL + Insulin + cells/mm2 of area in the Y axis, as the mean ±  SEM. Fasting control (FC) (blue bar), sham-operated (Sham) (lined bar) and RYGB rats (red bar). The data show the 
two studied periods in the X axis. 
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Fig. 7. Microphotograph of histologic studies. Left photos of FC (at 12 and 24 weeks after surgeries), middle photos of Sham (at 12 and 24 weeks after surgeries) and right photos 
of RYGB (at 12 and 24 weeks after surgeries) in jejunal samples. 7A. Villus weight of jejunal samples as μm in the Y axis, as the mean ±  SEM. Fasting control (FC) (blue bar), sham- 
operated (Sham) (lined bar) and RYGB rats (red bar). The data show the two studied periods in the X axis. 7B. Crypt depth as μm in the Y axis, as the mean ±  SEM. Fasting control 
(FC) (blue bar), sham-operated (Sham) (lined bar) and RYGB rats (red bar). The data show the two studied periods in the X axis. 7C. Ratio of superficial intestinal mucosae in the Y 
axis, as average differences since the FC measured at three months after surgeries. Fasting control (FC) (blue bar), sham-operated (Sham) (lined bar) and RYGB rats (red bar). The 
data show the two studied periods in the X axis. 
Fig. 8. 8A. SGLT1 Glucose transporter expression on the intestinal surface as SGLT1 + area/total intestinal area in the Y axis, as the mean ±  SEM. Fasting control (FC) (blue bar), 
sham-operated (Sham) (lined bar) and RYGB rats (red bar). The data show the two studied periods in the X axis. 8B. GLUT5 Glucose transporter expression on the intestinal surface 
as GLUT5 + area/total intestinal area in the Y axis, as the mean ±  SEM. Fasting control (FC) (blue bar), sham-operated (Sham) (lined bar) and RYGB rats (red bar). The data show the 
two studied periods in the X axis. 8C. GLUT1 Glucose transporter expression on the intestinal surface as GLTU1 + area/total intestinal area in the Y axis, as the mean ±  SEM. Fasting 
control (FC) (blue bar), sham-operated (Sham) (lined bar) and RYGB rats (red bar). The data show the two studied periods in the X axis. 
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possibilities remain to explain the decreased insulin secretion and 
beta-cell mass loss throughout the study. 
On the other hand, a decrease on the cell replication marker Ki67 
was observed in beta cells from RYGB-operated animals six month 
after surgery (Fig. 6C). Discarding the proliferative mechanism as a 
cellular response to stress. This result opposes previous reports, 
which described the proposed proliferation as the principal response 
to a stressful situation (Dor et al., 2004). We must insist these ex-
periences are based in different stressful situations. 
In this way, many authors have proposed beta-cell dediffer-
entiation as a pathophysiological mechanism that leads to a loss of 
beta-cell mass in a few situations, as a high insulin requirement for a 
long time (Wang et al., 2014). To investigate possible beta-cell ded-
ifferentiation, we tested the expression of a beta-cell marker, tran-
scription insulin promoter factor (Pdx-1) in rodent groups 
(Segerstolpe et al., 2016; Henry et al., 2019). Pdx-1 islet expression 
declined in the RYGB rats at the late stage of the experiment 
(Fig. 6A). This data supports a long-term loss of beta-cell identity in 
animals after RYGB, which explains the loss of beta-cell mass and 
insulin secretion throughout the study. This mechanism seems to 
explain beta-cell failure in T2DM (Talchai et al., 2012). 
In addition, an increase in alpha-cell mass was also observed at 
six, but not three, months after surgery in the RYGB rats (Fig. 5B). We 
exclude the possibility of an increased alpha-cell proliferation ratio 
(Fig. 6D). Thus, we considered beta-cell transdifferentiation more 
than beta-cell dedifferentiation in our model. Beta-cell transforma-
tion into alpha-cells has been reported as a consequence of beta-cell 
loss or insulin resistance in animal models (Tanday et al., 2020). 
Additionally, Pdx-1 activity is a repressor of the alpha-cell genetic 
program (Gao et al., 2014), and the normal proliferation ratio was 
observed in the alpha-cells from the RYGB rats. 
Supporting our proposal, high expression of Aristaless-related 
homeobox protein (Arx) was observed in the RYGB group twenty- 
four weeks after surgery but not at twelve weeks after surgery 
(Fig. 6B). Arx protein is an alpha-cell differentiation marker, whose 
expression in beta-cells converts these cells into alpha- or PP-cells 
(Courtney et al., 2014; Segerstolpe et al., 2016; Bakhti et al., 2019;  
Henry et al., 2019). 
Taken together, these data suggest a long-term beta-cell mass 
transdifferentiation into alpha-cell mass in RYGB rats, which can 
explain the loss of insulin secretion capacity at the end of the study. 
However, several questions remain uncertain. What factor that 
triggers this beta-cell response? Why does beta-cell transdiffer-
entiation occur in the long term? It´s well known that there are beta- 
cells subpopulations with different characteristics and even identity 
markers (Avrahami et al., 2017). These subpopulations could not be 
equally affected after these differentiation process. 
Analyzing the plasma insulin secretion in the RYGB group 
throughout the study, as we said above, an enhanced insulin se-
cretion pattern at the early stage of the assay was observed (Fig. 3D). 
Thinking about the high plasma insulin secretion pattern as a re-
sponse to high glucose absorption in the alimentary limb, we mea-
sured alimentary limb hypertrophy. The villus and crypt overgrowth 
from each group were compared, and a markedly higher villus 
height and a greater crypt depth were observed in the guts of the 
RYGB rats (Fig. 7). These data suggest a larger area for glucose ab-
sorption. To complete the study, sodium-glucose linked transporter 
(SGLT-1) and (GLUT-5) expression in the alimentary limbs was in-
vestigated. Statistical differences were observed in the glucose 
transporter densities between the control and RYGB groups at 
twelve and twenty-four weeks of the study (Fig. 8), confirming the 
results of Cavin et al. (2016). 
An increased absorption surface and a high GLUT-5 and SGLT-1 
density could justify significant glucose absorption in the gut after 
RYGB. This is supported by data shown at Figs. 3B and 3D, where we 
measured plasma levels of a non metabolizable-sugar as D-xylose. A 
high D-xylose absorption was observed in RYGB rats since the be-
ginning of the study, instead of FC or Sham groups. In fact, this would 
explain the need for high plasma insulin levels to maintain normal 
postprandial glycemia after RYGB, as Fig. 3 show. The requirement of 
high levels of insulin secretion for a long time would lead to beta-cell 
population stress and transdifferentiation into alpha-cells. As beta- 
cell marker loss and alpha-cell marker gain were observed many 
weeks after RYGB (Fig. 5). The loss of insulin-producing cells would 
be responsible for the long-term decrease in insulin secretion and 
postprandial high plasma glucose AUC at the end of the study 
(Fig. 3K and 3L). These data suggest a progressive and adaptive 
phenomenon that results in hyperglycemia. This would explain the 
reason for long-term T2DM resolution failure after RYGB. However, 
there are substantial differences between the endocrine pancreas 
and intestine of rodents and humans, which suggests the need for 
additional research on this issue. 
We report the mechanism that could explain the data reported in 
some patient five-ten years after underwent RYGB. These patient 
return to a diabetic status, which could be related to the anomalous 
glucose transport. This glucose absorption produces glycemic picks 
and hyperinsulinism. The consequence to this overload on beta-cells 
is a continuous stressful situation. Finally, stressed and exhausted 
beta-cell transdifferentiate to alpha-cell. This physiophathological 
mechanism needs to be confirmed in human clinic. But therefore, we 
could conclude that the RYGB might not be the desired treatment for 
some patients. 
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